Abstract
Previous studies have shown that ligands that bind to sigma-2 receptor/TMEM97 (σ2R/TMEM97), a transmembrane protein, have anxiolytic/antidepressant-like properties and relieve neuropathic pain-like effects in rodents. Despite medical interest in σ2R/TMEM97, little affective and pain behavioral characterization has been done using transgenic mice, which limits the development of σ2R/TMEM97 as a viable therapeutic target. Using wild-type (WT) and global Tmem97 knockout (KO) mice, we sought to identify the contribution of Tmem97 in modulating affective and pain-like behaviors using a battery of affective and pain assays, including open field, light/dark preference, elevated plus maze, forced swim test, tail suspension test, and the mechanical sensitivity tests. Our results demonstrate that female Tmem97 KO mice show less anxiety-like and depressive-like behaviors in light/dark preference and tail suspension tests but not in an open field, elevated plus maze, and forced swim tests at baseline. We next performed spared nerve injury in WT and Tmem97 KO mice to assess the role of Tmem97 in neuropathic pain-induced anxiety and depression. WT mice, but not Tmem97 KO mice, developed a prolonged neuropathic pain-induced depressive-like phenotype when tested ten weeks after nerve injury in females. Our results show that Tmem97 plays a role in modulating anxiety-like and depressive-like behaviors in naïve animals with a significant change in the presence of nerve injury in female mice. Overall, these data demonstrate that Tmem97 could be a target to alleviate affective comorbidities of pain disorders.
Significance Statement Chronic pain comorbidities, including anxiety and depression, present a significant public health challenge. Pharmacological agents developed to target the sigma-2 receptor/TMEM97 (σ2R/TMEM97) have demonstrated promising effects in alleviating anxiety, depression, and pain individually. Our work provides insight on the interaction between σ2R/TMEM97 and neuropathic pain-induced affective behaviors using transgenic mice, suggesting its potential as a novel therapeutic target for addressing both the pain and psychiatric components in complex chronic pain disorders.
Footnotes
We extend our gratitude to Dr. Joe Lombardo for technical assistance with imaging, Dr. Anny Treat for conducting pilot experiments, Tarik Ehsan for his assistance with animal behaviors and Mursal Hussein for colony and resource management.
This work was supported by NIH F31NS129269 (VMH), NIH R01DK115478 (BJK), NIH R61NS127271 (BJK), The Eugene McDermott Foundation (VMH).
The authors declare the following financial relationships. MSY, SFM, and TJP are co-founders of NuvoNuro Inc., which is focused on the development of ligands for sigma-2 receptor/TMEM97. No experimental compounds from the company were used in the present study.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Jump to comment: